The aforementioned results suggest that the Ganweikang tablet can reduce inflammation and apoptosis and enhance FAO by inhibiting NFκB and Caspase8 and activating PPARα, which protected the mice from NAFL and NASH suffering. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.